Passive Leg Raise and Mini-fluid Challenge Effect on Various Cardiac Output Surrogates for Fluid Responsiveness (PHOENIX)

Passive Leg Raise and Mini-fluid Challenge Effect on Various Cardiac Output Surrogates Such as Pulse Pressure Variation (PPV), End-tidal CO2 (Carbon Dioxide), Bioreactance (Stroke Volume Index -SVI) and Velocity Time Integral on Echocardiographic Exam for Fluid Responsiveness in Patients With Moderately Severe ARDS (Acute Respiratory Distress Syndrome)

In the critically ill population, fluid administration in an unstable patient is perhaps the most common intervention that is performed. Uncorrected hypovolemia with inappropriate vasopressors lead to organ hypoperfusion where as overzealous fluid administration especially in ARDS (Adult respiratory distress syndrome) can increase mortality. It has been estimated that only 50% of hemodynamically unstable critically ill patients are volume responsive, hence dynamic assessment of preload responsiveness has been proposed to better identify those individuals who would benefit from fluid bolus.

Study Overview

• Status: Recruiting
• Conditions: Fluid Responsiveness
• Intervention / Treatment: Diagnostic test: Passive leg raise, SVI via bioreactance, Echo based VTI

Detailed Description

Fluid responsiveness in patients with moderate to severe ARDS is crucial, as additional unnecessary fluid may be harmful. Various techniques of hemodynamic assessment exist, each with its own advantages and limitations. This study compares different techniques of preload responsiveness that include passive leg raise (PLR) and mini-fluid challenge induced changes in Pulse pressure variation (PPV), End tidal CO2, Bioreactance based Stroke volume index (SVI) and velocity time integral (VTI) on Echocardiogram.

Study protocol :

Baseline Echo with VTI will be obtained Bed side monitor will be set to display PPV and end tidal CO2 Baxter Starling system will be connected to the patient All baseline values will be recorded Tidal volume will be temporarily adjusted to 8 ml/kg , which will be reverted back to 6ml/kg after the measurements. This has proven to be a safe maneuver.

All the above hemodynamic assessments will be performed for eligible patients by measuring before and after PLR and repositioning to baseline. VTI will be estimated by bed side Echocardiogram. SVI will be estimated using the Starling system (Baxter). PPV and End tidal CO2 will be recorded from the bed side monitors.

Fluid responsiveness is presumed with a change in VTI of 10%. For these patients a mini-fluid challenge of 250 cc of crystalloids (NS, RL or Normosol) will be given over 10 min and PPV, VTI, End tidal CO2 and SVI will be recorded before and after fluid challenge. Patients with VTI change of < 10%, as non-responders, who will also be included in the analysis for assessment of reliability using the ROC curves. hemodynamic assessments and repeated fluid challenge will be considered as needed. Stability of vasopressor dose with maximum of 500 cc of crystalloid will be considered as positive fluid responder. This cohort of patients will be considered as gold standard for preload responsiveness and will be categorized based on a nominal scale. Patients who need higher vasopressor support despite 1L of crystalloid within 3 hours will be considered fluid non-responders.

Data collection:

De-identified data will be recorded. Age, BMI ( body mass index), Charleston co-morbidity index, baseline PPV, End-tidal CO2, SVI, VTI, post PLR, post fluid challenge, return to baseline, PF ratio, PEEP (positive end-expiratory pressure), SOFA (sequential organ function assessment) Score on the day of the test will be recorded.

Statistical Analysis:

Microsoft Excel will be used to record data on an institutional computer. Once the data is collected, it will be exported for statistical analysis. Jamovi will be utilized for statistical analysis. Baseline characteristics will be compared using a T-test if normative distribution or non-parametric test such as Mann Whitney U test. Reliability and accuracy will be detected using ROC curve assessment. In addition, the Youden index approach will be utilized to identify cut-offs of each of the variables and their change. (PPV, SVI,VTI and End tidal CO2). All the delta values will be compared with pearson correlation with a scatter plot and line of identity. Agreement between variables will be done using Bland-Altman analysis. If necessary, values will be transformed into Z scores. For all comparisons, a p-value of <0.05 was considered significant.

• Study Type: Observational
• Enrollment (Estimated): 64

Contacts and Locations

• Study Contact: Name: Ramakanth Pata; Phone Number: 320-240-2207; Email: cookybrey1@gmail.com

Study Locations

• United States
  • Minnesota
    • Saint Cloud, Minnesota, United States, 56303
      • Recruiting
      • St Cloud Hospital
      • Contact: Ramakanth Pata, MD FCCP; Phone Number: 320-240-2207; Email: cookybrey1@gmail.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Screening criteria:

1. New onset of hypotension: MAP < 65 mm HG for > 5 min
2. Escalation in Nor-epinephrine needs> 0.03 ug/kg/min
3. High MAP goal Low Urine output < 0.5ml/kg/hr for > 2 hours Elevated Lactate > 4 moles/L Decreased Lactate clearance (< 40%)
4. Bedside Echo Inc. VTI No obvious Hypovolemia No Low EF or No Pericardial effusion

Description

Inclusion Criteria:

• Age between 30 - 90 years
• Diagnosis of Vasodilatory Shock with no other obvious cause of hypotension
• Diagnosis of ARDS with PF ratio < 150 , PEEP > 8
• Patients who are under paralysis or deeply sedated, on a mechanical ventilator

Exclusion Criteria:

• Patients with arrhythmias including atrial fibrillation
• Patients with chest tube, intra-abdominal hypertension or with its risk factors
• Patients with structural heart disease including pulmonary hypertension (RVSP > 45) and heart failure
• Patients on extracorporeal support such as ECMO, CRRT or MCS.
• Patients with COPD with a premorbid FEV1 < 1.5 L
• Severe atherosclerotic vascular disease

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Fluid responder; Stability of vasopressor dose with maximum of 500 cc of crystalloids	Diagnostic test: Passive leg raise, SVI via bioreactance, Echo based VTI; No interventions other than fluid challenge
Fluid non responder; Escalating dose of vasopressors despite 1 L of crystalloid fluid challenge

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Vasopressor dose in Nor-epinephrine equivalents (NE) measured as mcg/kg/min	We shall assess the need for vasopressor dose e.g nor-epinephrine dose. If the dose remains constant after fluid bolus until 3 hours, we shall consider them fluid resposive. If the dose requirement goes up despite fluid bolus, we shall label them fluid un-responsive	3 hours after the initial passive leg raise

Collaborators and Investigators

• Sponsor: CentraCare
• Investigators: Principal Investigator: Ramakanth Pata, MD FCCP, Centracare health System

Publications and helpful links

General Publications

• Monnet X, Teboul JL. Passive leg raising: five rules, not a drop of fluid! Crit Care. 2015 Jan 14;19(1):18. doi: 10.1186/s13054-014-0708-5. No abstract available.
• Monnet X, Bataille A, Magalhaes E, Barrois J, Le Corre M, Gosset C, Guerin L, Richard C, Teboul JL. End-tidal carbon dioxide is better than arterial pressure for predicting volume responsiveness by the passive leg raising test. Intensive Care Med. 2013 Jan;39(1):93-100. doi: 10.1007/s00134-012-2693-y. Epub 2012 Sep 19.

Study record dates

Study Major Dates

• Study Start (Actual): July 1, 2023
• Primary Completion (Estimated): June 1, 2024
• Study Completion (Estimated): June 1, 2024

Study Registration Dates

• First Submitted: April 25, 2024
• First Submitted That Met QC Criteria: April 29, 2024
• First Posted (Actual): April 30, 2024

Study Record Updates

• Last Update Posted (Estimated): May 2, 2024
• Last Update Submitted That Met QC Criteria: April 30, 2024
• Last Verified: April 1, 2024

More Information

Terms related to this study

• Keywords: Passive leg raise; Pre-load responsiveness; Mini-fluid challenge
• Other Study ID Numbers: RAMPHOENIX

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No